# CADTH Health Technology Assessment Report
## Clinical Review Report: Onasemnogene Abeparvovec (Zolgensma)

**Agency:** Canadian Agency for Drugs and Technologies in Health (CADTH), Canada

**Report Type:** Clinical Review Report

**Publication Date:** May 2021

**Report URL:** https://www.ncbi.nlm.nih.gov/books/NBK584036/

---

## Executive Summary

### Drug Information

**Brand Name:** Zolgensma
**Generic Name:** Onasemnogene abeparvovec
**Manufacturer:** Novartis Pharmaceuticals Canada Inc.
**Drug Class:** Gene therapy
**ATC Code:** Not assigned

### Health Canada Indication

Onasemnogene abeparvovec has a Health Canada indication for the treatment of pediatric patients with:
- 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the SMN1 gene
- Three or fewer copies of the SMN2 gene, OR
- Infantile-onset SMA

### Reimbursement Request

The sponsor requested reimbursement for onasemnogene abeparvovec for the treatment of pediatric patients with 5q SMA consistent with the Health Canada indication.

### Treatment Regimen

- **Route of Administration:** Intravenous infusion
- **Dosing:** One-time infusion at a recommended dose of 1.1 Ã— 10^14 vector genomes (vg)/kg
- **Treatment Duration:** Single administration (gene therapy)

---

## 1. Clinical Evidence Review

### Pivotal Studies Reviewed

CADTH reviewed multiple clinical studies including:

**STR1VE Study:**
- Phase III, open-label, single-arm study
- Enrolled patients with SMA type 1
- Primary endpoint: event-free survival
- Key efficacy outcomes assessed

**START Study:**
- Phase I study
- Earlier cohort data
- Long-term follow-up information

**STR1VE-EU Study:**
- European cohort
- Additional safety and efficacy data

**SPR1NT Study:**
- Presymptomatic SMA patients
- Early intervention evaluation

### Study Design Characteristics

**Patient Population:**
- Pediatric patients with 5q SMA
- Predominantly SMA type 1 in symptomatic studies
- Presymptomatic patients in SPR1NT
- Specific SMN2 copy number criteria

**Comparators:**
- No active comparator in pivotal studies
- Comparison to natural history data
- External comparison to nusinersen data

**Study Limitations:**
- Single-arm design for pivotal studies
- Lack of randomized controlled trials
- Reliance on historical control data
- Limited long-term follow-up at time of review

---

## 2. Efficacy Results

### Event-Free Survival

**Key Findings:**
- Significant improvement compared to natural history
- Majority of patients avoided death or permanent ventilation
- Demonstrated clinical benefit in SMA type 1 population

### Motor Milestone Achievement

**Outcomes Assessed:**
- Independent sitting
- Standing with assistance
- Walking with assistance
- Comparison to natural history expectations

**Results:**
- Motor milestone achievement exceeded natural history expectations
- Time to milestone achievement varied by patient
- Early treatment associated with better outcomes

### Respiratory Function

- Reduced need for permanent ventilation
- Improved respiratory support independence
- Better outcomes than historical natural history data

### Feeding and Swallowing

- Improved ability to feed orally
- Reduced dependence on feeding tubes
- Better nutritional outcomes

### Overall Survival

- Improved survival compared to natural history
- Age-appropriate survival observed in treated patients
- Significant clinical benefit demonstrated

---

## 3. Safety and Harms

### Adverse Events Profile

**Common Adverse Events:**
- Elevated liver enzymes (transaminases)
- Thrombocytopenia
- Vomiting
- Pyrexia (fever)
- Upper respiratory tract infections

**Serious Adverse Events:**
- Acute liver injury
- Thrombotic microangiopathy (TMA)
- Respiratory events
- Some fatal cases reported in real-world use

### Risk Management

**Monitoring Requirements:**
- Liver function testing before and after infusion
- Platelet count monitoring
- Troponin-I monitoring
- Renal function assessment
- Complete blood count monitoring

**Corticosteroid Requirements:**
- Pre-treatment with corticosteroids required
- Post-treatment corticosteroid taper protocol
- Extended duration of corticosteroid use

### Contraindications and Precautions

**Contraindications:**
- Presence of anti-AAV9 antibodies above specified threshold

**Precautions:**
- Pre-existing liver disease
- Acute illness at time of treatment
- Thrombocytopenia
- Immunization considerations

---

## 4. Systematic Review Methods

### Literature Search Strategy

- Comprehensive search of multiple databases
- Clinical trials registries searched
- Grey literature review
- Sponsor submission review

### Inclusion Criteria

**Study Design:**
- Randomized controlled trials (RCTs) preferred
- Single-arm studies considered
- Long-term extension studies included

**Population:**
- Pediatric patients with 5q SMA
- All SMA types considered
- Various SMN2 copy numbers

**Intervention:**
- Onasemnogene abeparvovec at Health Canada approved dose

**Comparators:**
- Nusinersen
- Risdiplam
- Best supportive care
- Natural history

### Quality Assessment

- Risk of bias assessment conducted
- Study quality evaluated using appropriate tools
- Limitations identified and reported

---

## 5. Critical Appraisal

### Strengths of Evidence

- Clinically meaningful efficacy outcomes
- Consistent direction of effect across studies
- Alignment with mechanistic expectations
- Substantial benefit observed versus natural history

### Limitations and Uncertainties

**Study Design Issues:**
- Lack of randomized controlled trials
- Single-arm design introduces bias potential
- No direct head-to-head comparisons with other therapies
- Historical control limitations

**Generalizability Concerns:**
- Highly selected patient population
- Strict inclusion/exclusion criteria
- Limited data on older patients
- Limited data on patients with more advanced disease

**Long-Term Uncertainty:**
- Limited long-term durability data
- Unknown duration of treatment effect
- Potential need for additional therapies
- Durability of motor milestone achievements

**Comparative Effectiveness:**
- No direct comparison with nusinersen or risdiplam
- Difficult to assess relative efficacy
- Different patient populations in available studies
- Timing of treatment differs across studies

---

## 6. Stakeholder Input

### Patient Group Input

**Patient Experience with SMA:**
- Devastating impact on quality of life
- Progressive loss of motor function
- Significant caregiver burden
- High unmet medical need

**Patient Values and Preferences:**
- Desire for treatments that modify disease course
- Value of one-time treatment approach
- Importance of early diagnosis and treatment
- Quality of life considerations

### Clinician Input

**Clinical Expert Perspectives:**
- Transformative potential recognized
- Importance of early intervention
- Need for comprehensive patient selection
- Multidisciplinary care requirements
- Monitoring protocol importance

**Clinical Practice Considerations:**
- Infrastructure requirements for administration
- Patient selection criteria
- Optimal timing of treatment
- Integration with existing therapies

---

## 7. Economic Evidence

CADTH also conducted a separate pharmacoeconomic review (available as a companion report: NBK584026).

### Economic Review Key Findings

**Cost-Effectiveness Concerns:**
- High upfront cost of treatment
- Incremental cost-effectiveness ratio (ICER) exceeded commonly accepted thresholds
- Uncertainty in long-term cost-effectiveness
- Limited comparative economic data

**Economic Model Limitations:**
- Uncertainty in long-term efficacy assumptions
- Challenges in modeling ultra-rare diseases
- Limited comparative data for modeling
- Significant impact of time horizon assumptions

**Budget Impact:**
- Substantial budget impact anticipated
- Small patient population
- High cost per patient
- One-time treatment versus ongoing therapy cost considerations

---

## 8. CADTH Clinical Review Conclusions

### Clinical Effectiveness Conclusion

The CADTH clinical review concluded that:

**Efficacy:**
- Onasemnogene abeparvovec demonstrated clinically meaningful improvements in survival and motor function
- Benefits observed across multiple clinically important outcomes
- Particularly strong evidence in SMA type 1 population
- Earlier treatment associated with better outcomes

**Effectiveness Compared to Alternatives:**
- No direct comparative evidence available
- Indirect comparisons suggest comparable or potentially superior outcomes
- One-time administration offers practical advantages
- Complementary role to other available therapies possible

**Safety:**
- Manageable safety profile with appropriate monitoring
- Serious adverse events identified requiring vigilance
- Risk-benefit assessment favors use in appropriate patients
- Comprehensive monitoring protocols essential

### Key Limitations Requiring Consideration

1. **Evidence Gaps:**
   - Lack of randomized controlled trials
   - Limited long-term data
   - No head-to-head comparisons
   - Uncertainty about durability

2. **Clinical Uncertainty:**
   - Optimal patient selection criteria
   - Role relative to other therapies
   - Need for sequential or combination therapies
   - Long-term safety profile

3. **Implementation Considerations:**
   - Specialized center requirements
   - Patient identification and selection
   - Timing of treatment critical
   - Comprehensive monitoring needed

---

## 9. Clinical Review Committee Discussion

### Factors Considered

**Clinical Benefit:**
- Substantial improvement over natural history
- Meaningful outcomes for patients and families
- Addresses significant unmet need
- Potential for disease modification

**Innovation:**
- Novel gene therapy approach
- One-time treatment paradigm
- Addresses genetic cause of disease
- Represents significant scientific advance

**Uncertainties:**
- Long-term durability unknown
- Comparative effectiveness unclear
- Optimal treatment algorithms evolving
- Real-world effectiveness to be established

---

## 10. Recommendations Context

The CADTH clinical review provides evidence to inform:
- Provincial reimbursement decisions
- Clinical practice guidelines
- Patient access programs
- Treatment algorithms

### Implementation Considerations

**Infrastructure Requirements:**
- Specialized treatment centers
- Appropriate monitoring capabilities
- Multidisciplinary teams
- Long-term follow-up systems

**Patient Selection:**
- Genetic confirmation mandatory
- Clinical staging assessment
- Timing considerations critical
- Shared decision-making important

**Monitoring and Follow-Up:**
- Comprehensive monitoring protocols
- Registry participation valuable
- Long-term outcome assessment
- Safety surveillance essential

---

## 11. Related CADTH Reports

- Pharmacoeconomic Report: Onasemnogene Abeparvovec (Zolgensma) - NBK584026
- Other SMA treatment reviews (nusinersen, risdiplam)

---

## 12. Copyright and Access Information

**Copyright:** Canadian Agency for Drugs and Technologies in Health (CADTH), 2021

**Permissions:**
Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**Accessibility:**
The report is publicly available through NCBI Bookshelf and the CADTH website.

---

## Conclusion

The CADTH Clinical Review Report for onasemnogene abeparvovec (Zolgensma) concluded that the therapy is clinically effective in improving survival and motor function in pediatric patients with 5q SMA, particularly those with SMA type 1. While the clinical benefits are substantial, the review identified important limitations including:

1. Lack of randomized controlled trial data
2. Uncertainty about long-term durability of effect
3. Absence of direct comparative effectiveness data
4. High cost with cost-effectiveness exceeding commonly accepted thresholds

The review recognized that onasemnogene abeparvovec addresses a significant unmet medical need in a devastating pediatric disease, but recommended careful patient selection, comprehensive monitoring, and ongoing data collection to address remaining uncertainties.

Provincial reimbursement decisions must weigh the substantial clinical benefits against the high cost and remaining uncertainties about long-term effectiveness and comparative value relative to other available therapies.

---

**Report Compiled:** 2025-11-11
**Information Source:** CADTH Clinical Review Report available through NCBI Bookshelf and CADTH website
**Status:** Published clinical review report informing Canadian reimbursement decisions
